Rachel Koldej

Venetoclax or Ruxolitinib in Pre-Transplant Conditioning Lowers the Engraftment Barrier by Different Mechanisms in Allogeneic Stem Cell Transplant Recipients

Joanne E Davis, Kelei Du, Mandy J Ludford-Menting, Ashvind Prabahran, Eric Wong, Nicholas D Huntington, Rachel M Koldej, David S Ritchie

Journal article  |  2021  |  Frontiers in Immunology

Allogeneic stem cell transplantation (alloSCT) is utilised to cure haematological malignancies through a combination of conditioni..

Dissection of the bone marrow microenvironment in hairy cell leukaemia identifies prognostic tumour and immune related biomarkers

Rachel M Koldej, Ashvind Prabahran, Chin Wee Tan, Ashley P Ng, Melissa J Davis, David S Ritchie

Journal article  |  2021  |  SCIENTIFIC REPORTS

Hairy cell leukaemia (HCL) is a rare CD20+ B cell malignancy characterised by rare "hairy" B cells and extensive bone marrow (BM) ..

Clinical features, pathophysiology and therapy of Poor Graft Function Post Allogeneic Stem Cell Transplantation.

Ashvind A Prabahran, Rachel Koldej, Lynette Chee, David S Ritchie

Journal article  |  2021  |  Blood Adv

Poor graft function (PGF) defined by the presence of multi-lineage cytopenias in the presence of 100% donor chimerism, is a seriou..

Abstract CT208: Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL): The RaDD Study

Kate Manos, Richard Khor, Geoffrey Chong, Jodie Palmer, Michael MacManus, Colm Keane, Andrew M Scott, Jake Shortt, David Ritchie, Leonid Churilov, Laura Johnston, Tom Witkowski, Allison Barraclough, Sze Ting Lee, Wendi Lin, Rachel Koldej, Eliza Hawkes

Conference Proceedings  |  2021  |  Clinical Trials

Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL): The RaDD Study.

Kate Manos, Richard Khor, Geoffrey Chong, Jodie Palmer, Michael MacManus, Colm Keane, Andrew M Scott, Jake Shortt, David Ritchie, Leonid Churilov, Laura Johnston, Tom Witkowski, Allison Barraclough, Sze Ting Lee, Wendi Lin, Rachel Koldej, Eliza Hawkes

Conference Proceedings  |  2021  |  CANCER RESEARCH

IMMUNE PRIMING WITH NIVOLUMAB FOLLOWED BY NIVOLUMAB & RITUXIMAB IN 1 ST LINE TREATMENT OF FOLLICULAR LYMPHOMA: THE PHASE 2 1 ST FLOR STUDY

EA Hawkes, ST Lee, G Chong, M Gilbertson, A Grigg, L Churilov, T Fancourt, C Keane, D Ritchie, R Koldej, R Agarwal, K Manos, C Smith, K Houdyk, J Hawking, A Barraclough

Conference Proceedings  |  2021  |  Hematological Oncology

T cell receptor beta locus sequencing early post-allogeneic stem cell transplant identifies patients at risk of initial and recurrent cytomegalovirus infection

James A Kuzich, Yamuna Kankanige, Jerick Guinto, Georgina Ryland, Michelle McBean, Eric Wong, Rachel Koldej, Jenny Collins, David Westerman, David Ritchie, Piers Blombery

Journal article  |  2021  |  BONE MARROW TRANSPLANTATION

Identification of patients at risk of initial & recurrent cytomegalovirus (CMV) reactivation following allogeneic stem cell transp..

Immune priming with nivolumab followed by nivolumab and rituximab in first-line treatment of follicular lymphoma: The phase 2 1st FLOR study.

Eliza Anne Hawkes, Sze Ting Lee, Geoff Chong, Michael Gilbertson, Andrew Grigg, Leonid Churilov, Tineke Fancourt, Colm Keane, David Ritchie, Rachel Koldej, Rishu Agarwal, Kate Manos, Charmaine Smith, Kristen Houdyk, Joanne Hawking, Allison Barraclough

Conference Proceedings  |  2021  |  Journal of Clinical Oncology

7560 Background: Standard of care immunochemotherapy in front-line (1L) follicular lymphoma (FL) is highly efficacious but not wi..

Volatile anaesthesia and peri-operative outcomes related to cancer: a feasibility and pilot study for a large randomised control trial

JA Dubowitz, JP Cata, AP De Silva, S Braat, D Shan, K Yee, F Hollande, O Martin, EK Sloan, B Riedel

Journal article  |  2021  |  ANAESTHESIA

Published data suggest that the type of general anaesthesia used during surgical resection for cancer may impact on patient long-t..

Evaluation of risk factors for and subsequent mortality from poor graft function (PGF) post allogeneic stem cell transplantation

Ashvind Prabahran, Rachel Koldej, Lynette Chee, Eric Wong, David Ritchie

Journal article  |  2021  |  LEUKEMIA & LYMPHOMA

Poor Graft Function (PGF) is defined by multi-lineage cytopenias with complete donor chimerism post allogeneic transplantation, Ri..